nach oben

International Journal of Clinical Oncology

Erschienen in:

18.05.2018 | Original Article

The MDM2 rs937283 A > G variant significantly increases the risk of lung and gastric cancer in Chinese population

verfasst von: Bifeng Chen, Jieling Wang, Yucan Chen, Xiuli Gu, Xianhong Feng

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Background

Currently, the MDM2 promoter rs937283 A > G variant that is able to alter MDM2 gene expression has been widely studied to explore the association of MDM2 with cancer risk. In this report, we investigate the association of MDM2 rs937283 A > G variant with risk of lung cancer (LC) and gastric cancer (GC) in a Chinese population of Hubei province, which was followed by a meta-analysis.

Methods

The genotyping of rs937283 was performed by polymerase chain reaction-restriction fragment length polymorphism and confirmed by sequencing.

Results

The results of the present study showed that rs937283 was significantly associated with the risk of LC, and the factors of age, gender, smoking status and drinking status would affect such association. However, rs937283 was only associated with the risk of GC in male, smoking and drinking subgroups. The following meta-analysis demonstrated that rs937283 was associated with the overall cancer risk particularly in Chinese population, which reinforced our present finding. Moreover, the meta-analysis according to cancer types revealed that rs937283 was associated with retinoblastoma risk, but not squamous cell carcinoma risk.

Conclusion

Collectively, the MDM2 rs937283 A > G variant may be a valuable risk factor or diagnostic biomarker for Chinese cancer patients.

Chen W, Zheng R, Zeng H et al (2015) Epidemiology of lung cancer in China. Thorac Cancer 6(2):209–215. https://doi.org/10.1111/1759-7714.12169 CrossRefPubMedPubMedCentral

Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359(13):1367–1380. https://doi.org/10.1056/NEJMra0802714 CrossRefPubMed

Ajani JA, D’Amico TA, Almhanna K et al (2016) Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 14(10):1286–1312CrossRefPubMed

Crino L, Weder W, van Meerbeeck J et al (2010) Early stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(Suppl 5):v103–115. https://doi.org/10.1093/annonc/mdq207 CrossRefPubMed

Menges M, Hoehler T (2009) Current strategies in systemic treatment of gastric cancer and cancer of the gastroesophageal junction. J Cancer Res Clin Oncol 135(1):29–38. https://doi.org/10.1007/s00432-008-0425-z CrossRefPubMed

Lane DP (1992) Cancer. p53, guardian of the genome. Nature 358(6381):15–16. https://doi.org/10.1038/358015a0 CrossRefPubMed

Momand J, Zambetti GP, Olson DC et al (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69(7):1237–1245CrossRefPubMed

Honda R, Tanaka H, Yasuda H (1997) Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 420(1):25–27CrossRefPubMed

Tao W, Levine AJ (1999) Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53. Proc Natl Acad Sci USA 96(6):3077–3080CrossRefPubMedPubMedCentral

10.

Zhang X, Miao X, Guo Y et al (2006) Genetic polymorphisms in cell cycle regulatory genes MDM2 and TP53 are associated with susceptibility to lung cancer. Hum Mutat 27(1):110–117. https://doi.org/10.1002/humu.20277 CrossRefPubMed

11.

Wade M, Li YC, Wahl GM (2013) MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 13(2):83–96. https://doi.org/10.1038/nrc3430 CrossRefPubMedPubMedCentral

12.

Chen X, Sturgis EM, Lei D et al (2010) Human papillomavirus seropositivity synergizes with MDM2 variants to increase the risk of oral squamous cell carcinoma. Cancer Res 70(18):7199–7208. https://doi.org/10.1158/0008-5472.CAN-09-4733 CrossRefPubMedPubMedCentral

13.

Yu H, Huang YJ, Liu Z et al (2011) Effects of MDM2 promoter polymorphisms and p53 codon 72 polymorphism on risk and age at onset of squamous cell carcinoma of the head and neck. Mol Carcinog 50(9):697–706. https://doi.org/10.1002/mc.20806 CrossRefPubMedPubMedCentral

14.

Jin L, Xu L, Song X et al (2012) Genetic variation in MDM2 and p14ARF and susceptibility to salivary gland carcinoma. PLoS One 7(11):e49361. https://doi.org/10.1371/journal.pone.0049361 CrossRefPubMedPubMedCentral

15.

de Oliveira Reis AH, de Carvalho IN, de Sousa Damasceno PB et al (2012) Influence of MDM2 and MDM4 on development and survival in hereditary retinoblastoma. Pediatr Blood Cancer 59(1):39–43. https://doi.org/10.1002/pbc.24014 CrossRefPubMed

16.

Zhang F, Xu L, Wei Q et al (2013) Significance of MDM2 and P14 ARF polymorphisms in susceptibility to differentiated thyroid carcinoma. Surgery 153(5):711–717. https://doi.org/10.1016/j.surg.2012.11.009 CrossRefPubMed

17.

Yang J, Liu B, Li W et al (2013) Association of p53 and MDM2 polymorphisms with risk of human papillomavirus (HPV)-related esophageal squamous cell carcinoma (ESCC). Cancer Epidemiol 37(5):629–633. https://doi.org/10.1016/j.canep.2013.06.001 CrossRefPubMed

18.

Wang H, Ma K (2015) Association between MDM2 rs769412 and rs937283 polymorphisms with alcohol drinking and laryngeal carcinoma risk. Int J Clin Exp Pathol 8(6):7436–7440PubMedPubMedCentral

19.

Jiao Y, Jiang Z, Wu Y et al (2016) A functional polymorphism (rs937283) in the MDM2 promoter region is associated with poor prognosis of retinoblastoma in Chinese Han population. Sci Rep 6:31240. https://doi.org/10.1038/srep31240 CrossRefPubMedPubMedCentral

20.

Wang M, Zhang R, He J et al (2012) Potentially functional variants of PLCE1 identified by GWASs contribute to gastric adenocarcinoma susceptibility in an eastern Chinese population. PLoS One 7(3):e31932. https://doi.org/10.1371/journal.pone.0031932 CrossRefPubMedPubMedCentral

21.

Bosse Y, Amos CI (2017) A decade of GWAS results in lung cancer. Cancer Epidemiol Biomarkers Prev. https://doi.org/10.1158/1055-9965.EPI-16-0794 CrossRefPubMedPubMedCentral

22.

Lee YH (2015) Meta-analysis of genetic association studies. Ann Lab Med 35(3):283–287. https://doi.org/10.3343/alm.2015.35.3.283 CrossRefPubMedPubMedCentral

23.

Yu H, Li H, Zhang J et al (2016) Influence of MDM2 polymorphisms on squamous cell carcinoma susceptibility: a meta-analysis. Onco Targets Ther 9:6211–6224. https://doi.org/10.2147/OTT.S113417 CrossRefPubMedPubMedCentral

24.

Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16(3):1215CrossRefPubMedPubMedCentral

25.

Lau J, Ioannidis JP, Schmid CH (1997) Quantitative synthesis in systematic reviews. Ann Intern Med 127(9):820–826CrossRefPubMed

26.

Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22(4):719–748PubMed

27.

DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7(3):177–188CrossRefPubMed

28.

Sterne JA, Gavaghan D, Egger M (2000) Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature. J Clin Epidemiol 53(11):1119–1129CrossRefPubMed

29.

Begg CB (2002) A comparison of methods to detect publication bias in meta-analysis by Macaskill P, Walter SD, Irwig L. Stat Med 2001 20:641–654. https://doi.org/10.1002/sim.1162 (Stat Med 21(12):1803; author reply 1804) CrossRef

30.

Khan N, Afaq F, Mukhtar H (2010) Lifestyle as risk factor for cancer: evidence from human studies. Cancer Lett 293(2):133–143. https://doi.org/10.1016/j.canlet.2009.12.013 CrossRefPubMedPubMedCentral

31.

Hartgrink HH, Jansen EP, van Grieken NC et al (2009) Gastric cancer. Lancet 374(9688):477–490. https://doi.org/10.1016/S0140-6736(09)60617-6 CrossRefPubMedPubMedCentral

32.

Herceg Z, Vaissiere T (2011) Epigenetic mechanisms and cancer: an interface between the environment and the genome. Epigenetics 6(7):804–819. https://doi.org/10.4161/epi.6.7.16262 CrossRefPubMed

33.

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674. https://doi.org/10.1016/j.cell.2011.02.013 CrossRefPubMed

34.

Khurana E, Fu Y, Colonna V et al (2013) Integrative annotation of variants from 1092 humans: application to cancer genomics. Science 342(6154):1235587. https://doi.org/10.1126/science.1235587 CrossRefPubMedPubMedCentral

Titel: The MDM2 rs937283 A > G variant significantly increases the risk of lung and gastric cancer in Chinese population
verfasst von: Bifeng Chen
Jieling Wang
Yucan Chen
Xiuli Gu
Xianhong Feng
Publikationsdatum: 18.05.2018
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 5/2018
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-018-1295-2

Springer Medizin

The MDM2 rs937283 A > G variant significantly increases the risk of lung and gastric cancer in Chinese population

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

A prospective feasibility study applying the ACOSOG Z0011 criteria to Japanese patients with early breast cancer undergoing breast-conserving surgery

Validation of the 8th edition of the AJCC/UICC TNM staging system for tongue squamous cell carcinoma

Treatment outcomes of patients with spinal metastases derived from hepatocellular carcinoma

Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia

Relationships between sunitinib plasma concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma

Feasibility study of postoperative adjuvant chemotherapy with S-1 in patients with biliary tract cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie